lysylglutamic-acid and Cardiomyopathy--Hypertrophic

lysylglutamic-acid has been researched along with Cardiomyopathy--Hypertrophic* in 1 studies

Other Studies

1 other study(ies) available for lysylglutamic-acid and Cardiomyopathy--Hypertrophic

ArticleYear
[Functional regulation of genome with peptide bioregulators by hypertrophic cardiomyopathy (by patients and relatives)].
    Georgian medical news, 2013, Issue:225

    In this paper, a comparative study of the functional genome indicators using lymphocyte cultures of patients with hypertrophic cardiomyopathy (HCM) and their first relatives. Studies conducted both in intact cultures and cultures exposed to the influence of peptide - bioregulators Epithalon, Vilon and Livagen. Last (Livagen) tested at separate and joint application with cobalt chloride salt. As indicated according to the results of the analysis, the cells of the individuals with HCM and their first relatives were characterized by higher frequency of spontaneous quantitative - structural disorders in comparison with the cells of healthy individuals. The findings suggest a different effect of bioregulators. The most effective protective action in relation normalization of functional parameters of the genome shows Epithalon for lowering the level of chromosomal instability in patients with hypertrophic cardiomyopathy and relatives of patients with HCM. On the basis of identified protective action Epithalon concludes prospects of its application in the development of preventive measures for individuals at increased risk of morbidity HCM.

    Topics: Aneuploidy; Cardiomyopathy, Hypertrophic; Chromatin; Chromosome Aberrations; Dipeptides; Female; Genome, Human; Humans; Lymphocytes; Male; Oligopeptides; Peptides; Primary Cell Culture

2013